Prostate Cancer News

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to prostate cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of prostate cancer treatment and survivorship.

Share

Prostate Cancer News


Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (July 26, 2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published... Continue Reading

Study Suggests Men with Metastatic Prostate Cancer Should Be Tested for Inherited Mutations (July 14, 2016)

Ever since inherited mutations in BRCA genes were first linked to breast and ovarian cancer two decades ago, this information has been used as a way to help empower women. Those who have the mutations... Continue Reading

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (June 13, 2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing... Continue Reading

Addition of Radiation Improves Survival in High-Risk Prostate Cancer (May 18, 2016)

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were... Continue Reading

Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers (May 17, 2016)

The use of chemotherapy following a radical prostatectomy delays the time to cancer progression among men with prostate cancer who are at a high risk of developing a recurrence.  These results were recently... Continue Reading

Protons & Prostate Cancer Treatment (April 21, 2016)

By John Leifer There are few things more mind-numbing than nuclear physics. Fortunately, you don’t have to be a physicist to understand proton therapy. Your goal, after all, is not to understand sub-atomic... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (April 19, 2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer. ... Continue Reading

Shorter, Intensive Radiation Can Be Recommended in Early Prostate Cancer (April 14, 2016)

DURHAM, N.C. –- Giving early-stage prostate cancer patients a slightly higher daily dose of radiation can cut more than two weeks from the current treatment regimen without compromising cancer control,... Continue Reading

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (March 14, 2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy... Continue Reading

More Prostate Cancer News

Latest Prostate Cancer News By Stage


Screening and Prevention

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer... Continue Reading

Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)

Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading

PSA Testing May Be Appropriate for Some Men (July 25, 2012)

The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading

Side Effects of Prostate Cancer Treatment Persist Long-Term (July 5, 2012)

Men who are treated for prostate cancer may continue to suffer from side effects 10 years after treatment, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, more than 192,000 men are diagnosed... Continue Reading

More Screening and Prevention

Early Stage I-II (A-B)

Protons & Prostate Cancer Treatment (April 21, 2016)

By John Leifer There are few things more mind-numbing than nuclear physics. Fortunately, you don’t have to be a physicist to understand proton therapy. Your goal, after all, is not to understand sub-atomic particles, but to cut through the hype surrounding... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (April 19, 2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak... Continue Reading

Shorter, Intensive Radiation Can Be Recommended in Early Prostate Cancer (April 14, 2016)

DURHAM, N.C. –- Giving early-stage prostate cancer patients a slightly higher daily dose of radiation can cut more than two weeks from the current treatment regimen without compromising cancer control, according to a national study led by a Duke Cancer... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Men Who Forgo Aggressive Treatment for Prostate Cancer Don’t Receive Appropriate Monitoring (December 9, 2015)

An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance – closely monitoring their cancer – rather than aggressive treatment to avoid the debilitating potential side effects of surgery and radiation,... Continue Reading

More Early Stage I-II (A-B)

Locally Advanced Stage III (C)

Protons & Prostate Cancer Treatment (April 21, 2016)

By John Leifer There are few things more mind-numbing than nuclear physics. Fortunately, you don’t have to be a physicist to understand proton therapy. Your goal, after all, is not to understand sub-atomic particles, but to cut through the hype surrounding... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Prostate Cancer in the News: Research, Treatment-Decision Making, & Promising New Therapies (January 29, 2015)

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to prostate cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports... Continue Reading

More Locally Advanced Stage III (C)

Metastatic Stage IV (D)

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (July 26, 2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Prostvac® Vaccine Promising in Treatment of Metastatic Castration-Resistant Prostate Cancer (June 1, 2015)

The prostate cancer vaccine Prostvac® (rilimogene galvacirepvec/rilimogene glafolivec) may be active in combination with Yervoy® (ipilimumab) in the treatment of metastatic prostate cancer that does not respond to hormone therapy. These findings were... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

CancerConnect News: The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported... Continue Reading

More Metastatic Stage IV (D)

Refactory/Recurrent

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (July 26, 2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (June 13, 2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (November 4, 2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

CancerConnect News: The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported... Continue Reading

<More Refactory/Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS